| Property | Value |
|
has major subject area list
|
Multiple Myeloma; Neoplasm, Residual
|
|
has minor subject area list
|
Clinical Trials as Topic; Diagnostic Imaging; Disease Management; Drug Collateral Sensitivity; Global Health; Humans; Molecular Diagnostic Techniques; Neoplastic Cells, Circulating; Outcome Assessment, Health Care; Population Surveillance; Reproducibility of Results; Smoldering Multiple Myeloma; Time Factors
|
|
information resource reference
|
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
|
|
label
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
|